Episode Details
Back to EpisodesA September Skip, The Bullish Case for Viking Therapeutics, and Lassoing the Laggards 8/19/25
Published 7 months, 3 weeks ago
Description
Why the Fed could skip a September cut altogether, despite higher inflation data. BTIG makes the case for sticking with Viking Therapeutics despite disappointing weight loss drug trial data. Plus, the laggards our traders says to buy now.